ArticleJournal of fungi (Basel, Switzerland)2018
Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India.
Article in Journal of fungi (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 216 citations in OpenAlex.
- Diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis: a systematic review and meta-analysis.The Journal of laryngology and otology · 2022Pooled it
- Coincidence or reality behind Mucormycosis, diabetes mellitus and Covid-19 association: A systematic review.Journal de mycologie medicale · 2022Pooled it
- Acute Invasive Fungal Rhino-Orbital Sinusitis: Current Concepts and Controversies.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Orbital mucormycosis post-COVID-19: Demographics, clinical features, and treatment outcomes.Journal of family medicine and primary care · 2025Article
- Diverse Presentations of Invasive Aspergillus and Mucorales Infections in Immunocompromised Patients: A Case Series.Cureus · 2025Article
- The Aftermath of the Battle Between Covid-19 & Invasive Fungal Sinusitis: A long Term Prospective Study.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Mucormycosis and Hearing: A Hospital-Based Study.International archives of otorhinolaryngology · 2025Article
- Pterygopalatine Fossa- A Keystone Area in Disease Progression and Management in Rhino-Oculo-Cerebral Mucormycosis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- The Rising Threat of Mucormycosis: Oman's Experience Before and During the COVID-19 Pandemic.Journal of fungi (Basel, Switzerland) · 2024Article
- A clinical study of rhino-orbital-cerebral mucormycosis during the COVID-19 pandemic in western Maharashtra.Journal of family medicine and primary care · 2024Article
- Mucormycosis during COVID-19 era: A retrospective assessment.Infectious medicine · 2024Review
- Baseline findings of a multicentric ambispective cohort study (2021-2022) among hospitalised mucormycosis patients in India.Mycology · 2024Article
- IntegratingCurrent research in microbial sciences · 2024Article
- A rare presentation of rhino-orbital-cutaneous mucormycosis in an immunocompetent patient: a case report.The Pan African medical journal · 2024Article
- Insulin and early debridement keys to survival in-COVID 19 associated mucormycosis patients(CAM)- An experience from tertiary care hospital In India.Journal of diabetes and metabolic disorders · 2023Article
- Article
- Reconstructive cranial surgery for invasive and non-responsive mucormycosis.BMJ case reports · 2023Article
- Rhino-Orbito-Cerebral Mucormycosis (ROCM) in COVID-19 Patients.Journal of family medicine and primary care · 2023Article
- Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis is an emerging opportunistic fungal infection. Increasing immunocompromization, widespread use of antibacterial and antifungal agents (such as voriconazole prophylaxis), carcinomas, transplantation and lifestyle diseases such as diabetes are the main contributors to this situation. The predominant clinical manifestations of mucormycosis vary from host to host, with rhino-orbital-cerebral, pulmonary, cutaneous, and gastrointestinal infections being the most common. In India, the prevalence of mucormycosis is approximately 0.14 cases/1000 population, which is about 70 times the worldwide-estimated rate for mucormycosis. The present study was undertaken over a period of five years (January 2009-December 2014) to determine the prevalence of mucormycosis. The samples suspected of mucormycosis were examined by direct KOH wet mount and cultured on Sabouraud's dextrose agar without actidione and on blood agar as per standard mycological techniques. Histopathological correlation was done for most of the cases. Antifungal susceptibility testing was performed by the EUCAST reference method. We identified a total of 82 cases of mucormycosis out of a total of 6365 samples received for mycological culture and examination during the said time period. Out of these, 56 were male patients and 27 were females. Most common presentation was rhino-orbito-cerebral (37), followed by cutaneous (25), pulmonary (14), oral cavity involvement (4) and gastrointestinal (2). The most common risk factors were diabetes and intramuscular injections. The fungi isolated were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.